VidaMed v Prosurge
This article was originally published in The Gray Sheet
Executive Summary
Federal judge grants VidaMed summary judgment in support of the company's assertion that ProSurge infringes a VidaMed patent by "asking, encouraging and otherwise soliciting physicians" to use ProSurge's infringing Opal and Opal Flex products for treatment of benign prostatic hyperplasia. The California federal court rules that the VidaMed patent covered basic methods for treatment involving the use of one or more radiofrequency electrodes deployed transurethrally to ablate prostatic tissue